Ratings SD BioSensor, Inc

Equities

A137310

KR7137310009

End-of-day quote Korea S.E. Other stock markets 03:30:00 13/05/2024 am IST			5-day change	1st Jan Change
10,340 ^KRW	-2.82%		-1.90%	-9.62%

2023	SD Biosensor, Inc announced that it has received KRW 226.0893359 billion in funding from BioNote, Inc.	CI
2023	SD Biosensor, Inc announced that it expects to receive KRW 226.0893359 billion in funding from BioNote, Inc.	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in debt and has limited leeway for investment
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SD BIOSENSOR, INC	-9.62%	951M		-
BIOMÉRIEUX	-3.58%	12.64B		B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-1.48%	8.46B		B-
DIASORIN S.P.A.	+8.70%	5.66B		B
LANTHEUS HOLDINGS, INC.	+24.18%	5.27B		C
AUTOBIO DIAGNOSTICS CO., LTD.	-4.58%	4.49B		C
10X GENOMICS, INC.	-51.57%	3.11B		D+
ANDON HEALTH CO., LTD.	+16.25%	2.87B	-	-
MYRIAD GENETICS, INC.	+31.40%	2.31B		C
GUANGZHOU WONDFO BIOTECH CO.,LTD	-4.08%	1.89B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes